EP Patent

EP3473642A2 — Compositions and methods of using islet neogenesis peptides and analogs thereof

Assigned to Shenzhen Hightide Biopharmaceutical Ltd · Expires 2019-04-24 · 7y expired

What this patent protects

Provided herein are peptides and analogs of INGAP and HIP peptides and modifications thereof. Also provided herein are said peptides, analogs or modifications thereof for use in methods of treating various diseases and conditions including impaired pancreatic function and metabol…

USPTO Abstract

Provided herein are peptides and analogs of INGAP and HIP peptides and modifications thereof. Also provided herein are said peptides, analogs or modifications thereof for use in methods of treating various diseases and conditions including impaired pancreatic function and metabolic diseases, for example, diabetes (types 1 and 2). The uses also include islets induction, expansion and proliferation for transplantation, promoting neuroprotection or nerve regeneration, promoting liver regeneration or inhibition inflammation.

Drugs covered by this patent

Patent Metadata

Patent number
EP3473642A2
Jurisdiction
EP
Classification
Expires
2019-04-24
Drug substance claim
No
Drug product claim
No
Assignee
Shenzhen Hightide Biopharmaceutical Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.